Blue Earth announces first UK patient received prostate cancer injection
Esme Needham | January 13, 2026 | News story | Research and Development | Blue Earth Therapeutics, Oncology, prostate cancer
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first UK patient has received its investigational Lutetium rhPSMA-10.1 injection for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
The dosing took place as part of an ongoing phase 2 clinical trial at St Bartholomew’s Hospital and The James Cook University Hospital. Patients are also being screened for participation in the study at other UK sites.
Five-year survival rates for patients newly diagnosed with metastatic prostate cancer currently stand at 36.6%. Deaths from prostate cancer have declined over the past 30 years, but the creation of effective therapies is still vital. Estimates suggest that in 2025, there will be over 50,000 new metastatic prostate cancer cases in the US (including cases of disease recurrence following earlier diagnosis).
The aim of the phase 2 trial is to optimise dosing. High doses of radiation may be beneficial if administered during early treatment cycles, a time when tumour burden is often high. Previous studies of radioligand therapies have generally used fixed dosing. Blue Earth’s study is aligned with the US Food and Drug Administration (FDA) Project Optimus., which is designed to encourage dose optimisation.
The trial’s main measure of efficacy will be the proportion of patients who achieve a reduction in prostate-specific antigen (PsA) levels greater than 50%.
David Gauden, CEO of Blue Earth, said: “Dosing the first patients in the UK marks a pivotal step in our mission to advance radiopharmaceutical treatments for prostate cancer. With our company being headquartered in the UK, this milestone reflects our commitment to the UK’s life sciences vision to accelerate clinical research and translate innovation into meaningful patient benefit.”
Related Content
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …
Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland …
